Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715868 | 0.84 | CTSS (0.57) | SMN1; SMN2MAPTLMNATP53RAB9A | |
| SCHEMBL13258279 | 0.84 | HDAC8 (0.51) | SMN1; SMN2MAPTRAB9ACTSBCTSS | |
| SCHEMBL13258134 | 0.84 | HDAC8 (0.51) | SMN1; SMN2MAPTRAB9ACTSBCTSS | |
| SCHEMBL31323267 | 0.84 | HDAC8 (0.51) | SMN1; SMN2MAPTRAB9ACTSBCTSS | |
| SCHEMBL3403454 | 0.83 | KAT6A (0.60) | SMN1; SMN2MAPTLMNARAB9AGAA | |
| SCHEMBL30216106 | 0.83 | KAT6A (0.60) | SMN1; SMN2MAPTLMNARAB9AGAA | |
| SCHEMBL1752669 | 0.82 | TAAR1 (0.55) | SMN1; SMN2RAB9ACTSBCTSSCTSK | |
| SCHEMBL26814992 | 0.81 | JAK2 (0.49) | SMN1; SMN2MAPTLMNARAB9AJAK2 | |
| SCHEMBL1752666 | 0.81 | HDAC4 (0.65) | CTSBCTSSCTSKJAK2HDAC4 | |
| SCHEMBL25342412 | 0.81 | RAB9A (0.56) | SMN1; SMN2MAPTLMNATP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-14 | — | — | US | disclosed |
| EP-4225730-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | The Regents of the University of California (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076507-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | PRMT8, SIRT1, PRMT3 | SMN1; SMN2 29/4885MAPT 31/4885LMNA 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.